HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Neuromuscular Junction Diseases

Subscribe to New Research on Neuromuscular Junction Diseases

Conditions characterized by impaired transmission of impulses at the NEUROMUSCULAR JUNCTION. This may result from disorders that affect receptor function, pre- or postsynaptic membrane function, or ACETYLCHOLINESTERASE activity. The majority of diseases in this category are associated with autoimmune, toxic, or inherited conditions.

Also Known As:

Neuromuscular Junction Disorders; Neuromuscular Junction Toxic Disorders; Neuromuscular Transmission Disorders; Toxic Disorders, Neuromuscular Junction; Neuromuscular Junction Disease; Neuromuscular Junction Disorder; Neuromuscular Transmission Disorder

Networked: 24 relevant articles (1 outcomes, 3 trials/studies) for this Disease, Comments

Relationship Network

Disease Context: Research Results

Nervous System Diseases: 3600
- Neuromuscular Diseases: 757
  - Neuromuscular Junction Diseases: 24

Related Diseases

1.	Muscular Diseases (Myopathy)
2.	Multiple Sclerosis
3.	Central Nervous System Diseases (CNS Diseases)
4.	Myasthenia Gravis
5.	Miller Fisher Syndrome (Fisher Syndrome)

Experts

1.	Kaminski, Henry J: 3 articles (02/2008 - 11/2002)
2.	Vincent, Angela: 2 articles (07/2008 - 05/2003)
3.	Medof, M Edward: 2 articles (12/2007 - 11/2002)
4.	Lin, Feng: 2 articles (12/2007 - 11/2002)
5.	Tan, Li-Ming: 1 article (02/2010)
6.	Huang, Sha: 1 article (02/2010)
7.	Gilhus, Nils Erik: 1 article (03/2009)
8.	Aboussouan, L S: 1 article (01/2009)
9.	Luchanok, Uladzimir: 1 article (02/2008)
10.	Zhou, Yuefang: 1 article (12/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Neuromuscular Junction Diseases:

1.	Intravenous Immunoglobulins (IVIG)FDA Link 09/01/2006 - "INTRODUCTION: Although IVIg is highly effective in several autoimmune neuromuscular disorders (neuropathies, myopathies and neuromuscular junction disorders), its effectiveness in autoimmune or neuroinflammatory CNS diseases, with the exception of multiple sclerosis, has not been explored. " Order ALL the reference details at left...
2.	AutoantibodiesIBA 07/01/2008 - "Autoantibodies in neuromuscular transmission disorders." 01/01/2006 - "This study is aimed to evaluate cochlear function in myasthenia gravis (MG), a neuromuscular transmission disorder caused by ACh receptor autoantibodies. " 03/01/2009 - "Myasthenia gravis (MG) is an autoimmune neuromuscular transmission disorder where well-defined autoantibodies against muscle and muscle cell membrane molecules are directly pathogenetic. " 02/01/2008 - "Despite the recognition of a new autoantigen, the muscle-specific kinase protein in generalized myasthenia gravis, it has been found to be only rarely identified in ocular myasthenia patients and therefore the majority of patients lack detectable autoantibodies and confirmation of a neuromuscular transmission disorder relies on specialized testing of single-fiber electromyography. " 11/01/2002 - "Myasthenia gravis (MG) is an autoimmune neuromuscular transmission disorder characterized by loss of acetylcholine receptors (AChR's) due primarily to the production of anti-AChR autoantibodies. " Order ALL the reference details at left...
3.	Amlodipine (Norvasc)FDA LinkGeneric 09/01/2007 - "SIGNIFICANCE: The effects of verapamil and amlodipine are at a level, which may cause misinterpretation of single fiber electromyography studies carried out to investigate neuromuscular junction disorders." Order ALL the reference details at left...
4.	Verapamil (Calan)FDA LinkGeneric 09/01/2007 - "SIGNIFICANCE: The effects of verapamil and amlodipine are at a level, which may cause misinterpretation of single fiber electromyography studies carried out to investigate neuromuscular junction disorders." Order ALL the reference details at left...
5.	tebufenozide (Mimic)IBA 01/01/2000 - "Electrodiagnostic study findings in patients with presumed neuromuscular junction disorders may mimic findings suggestive of a neuropathic process, or the bioassay for botulism may be falsely positive in patients with Fisher Syndrome." Order ALL the reference details at left...
6.	Cholinergic ReceptorsIBA 02/01/2003 - "We explored the pathophysiological relevance of this phenomenon in patients with myasthenia gravis (MG) and rats with experimental autoimmune MG (EAMG), neuromuscular junction diseases with depleted acetylcholine receptors. " 11/01/2002 - "Myasthenia gravis (MG) is an autoimmune neuromuscular transmission disorder characterized by loss of acetylcholine receptors (AChR's) due primarily to the production of anti-AChR autoantibodies. " 12/15/2007 - "Myasthenia gravis (MG) is a neuromuscular transmission disorder in which damage to acetylcholine receptors (AChR) on motor endplates by autoantibody-induced complement attack causes muscle weakness. " Order ALL the reference details at left...
7.	Complement System Proteins (Complement)IBA 01/01/2007 - "Myasthenia gravis (MG) is a chronic, T-cell dependent, antibody and complement-mediated autoimmune neuromuscular transmission disorder. " 12/15/2007 - "Myasthenia gravis (MG) is a neuromuscular transmission disorder in which damage to acetylcholine receptors (AChR) on motor endplates by autoantibody-induced complement attack causes muscle weakness. " Order ALL the reference details at left...
8.	AntibodiesIBA 05/01/2003 - "The role of antibodies to specific neuronal and muscle ion channels in the etiology of neuromuscular transmission disorders is now well accepted. " 02/01/2010 - "Myasthenia gravis (MG) is an autoimmune neuromuscular junction disease mediated by antibodies against the acetylcholine receptor (AChR). " Order ALL the reference details at left...
9.	Guanidine (Guanidine Nitrate)FDA Link 09/01/1986 - "The pharmacokinetic parameters of guanidine hydrochloride were analysed in dogs with an hereditary neuromuscular transmission disorder by the use of 14C-guanidine hydrochloride. " Order ALL the reference details at left...
10.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/01/2003 - "In up to 90 per cent of cases IgG autoantibodies to the nicotinic acetylcholine receptor are detectable which mediate the neuromuscular transmission disorder. " Order ALL the reference details at left...

Therapies and Procedures

1.	Electrodes (Electrode) 06/01/2007 - "PURPOSE: To map the motor end-plate area of the anconeus muscle and define the best place for positioning the recording electrodes in repetitive stimulation tests (RST) for the diagnosis of neuromuscular transmission disorders. " 06/01/2003 - "2) EMG and evoked EMG: These tests are applied for the diagnosis of neurogenic, myogenic and neuromuscular junction disorder, and also the single fiber EMG using micro needle electrode is useful for the diagnosis of myasthenia gravis. " Order ALL the reference details at left...
2.	Breathing Exercises (Qigong) 01/01/2009 - "These challenges are compounded by the variety of exercise prescriptions (aerobic, muscle strengthening, and respiratory muscle training) and the variety of neuromuscular disorders (muscular, motor neuron, motor nerve root, and neuromuscular transmission disorders). " Order ALL the reference details at left...

blog comments powered by Disqus

TREATMENT OPTIONS
for Neuromuscular Junction Diseases,
Ranking and Evidence

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 1 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>